Treatment of Moderate-to-Severe Ulcerative Colitis in Advanced Therapy-Naive Adult Outpatients
This protocol covers the management of moderate-to-severe ulcerative colitis (Mayo Clinic score 6–12) in adult outpatients who have had no prior exposure to advanced therapies.
Clinical Scenario
Moderate-to-severe UC in an adult outpatient, naive to advanced (biologic or small-molecule) therapies. Disease activity scores of 6–12 define this range; clinical remission is a Mayo Clinic score below 3, with no individual subscore above 1.
Treatment Approach
Current evidence supports early (top-down) initiation of an advanced therapy rather than gradual step-up after conventional agents. The full protocol specifies which advanced agents — and under what conditions combination with an immunomodulator — are recommended for this population.
Clinical Targets
- Symptomatic response within 3 months of initiation
- Symptomatic and biochemical (clinical) remission within 3–6 months
- Endoscopic improvement or remission within 6–12 months
References
DOI: 10.1053/j.gastro.2024.10.001
- In adult outpatients with moderate-to-severe UC who are naïve to advanced therapies, the AGA suggests using a HIGHER efficacy medication (infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab) OR an INTERMEDIATE efficacy medication (golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab), rather than a LOWER efficacy medication (adalimumab).
- Scores of 6–12 correspond to moderate-to-severe disease activity, whereas clinical remission is most consistently defined as Mayo Clinic score <3, with no individual subscore >1.
- In adult outpatients with moderate-severe UC, the AGA suggests early use of advanced therapies with or without immunomodulator therapy, rather than gradual step up after failure of 5-ASAs.
- In adult outpatients with moderate-to-severe UC, the AGA suggests the use of infliximab in combination with an immunomodulator over infliximab or an immunomodulator alone.
- In adult outpatients with moderate-to-severe UC, the AGA suggests the use of adalimumab or golimumab in combination with an immunomodulator over adalimumab, golimumab or immunomodulator monotherapy.
- Initiation of advanced therapy should be followed by monitoring for symptomatic response within 3 mo of initiation, symptomatic and biochemical remission within 3–6 mo, and endoscopic improvement/remission within 6–12 mo.